scholarly journals Recurrence of borderline ovarian tumors: a survival analysis

2021 ◽  
Vol 10 (10) ◽  
pp. 3856
Author(s):  
Sahana Punneshetty ◽  
Anitha Thomas ◽  
Dhanya Susan Thomas ◽  
Rachel George Chandy ◽  
Sherin Daniel ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Good Prognosis ◽  
Ovarian Tumors ◽  
Benign Tumors ◽  
Borderline Ovarian Tumor ◽  
Non Invasive ◽  
Borderline Ovarian Tumors ◽  
Ovarian Epithelial Tumors ◽  
Fertility Sparing ◽  
Reproductive Aged Women

Background: Borderline ovarian tumors are non-invasive tumors that display greater epithelial proliferation and cytological atypia than benign tumors, but less than carcinomas. They may be treated conservatively in young women, however there is a concern for recurrence and progression to frank malignancy. We aimed to study the clinicopathological features of borderline ovarian tumors and their risk of recurrence.Methods: We reviewed the electronic and paper charts of all borderline ovarian tumors operated between January 1, 2001 and December 31, 2019 at a tertiary level teaching hospital in India. Descriptive statistics such as proportions and means were used. A survival analysis was done for recurrence and death.Results: A total of 93 borderline ovarian tumor patients were identified. The most common histology in our study was mucinous 60 (63%) followed by serous 28 (29%). Ninety two (99%) of them were stage I at diagnosis. Microinvasion was present in 27 (26%) of the cases. Out of the 30 fertility sparing operations performed (unilateral salpingo-oophorectomy/cytectomy), 4 (13%) had recurrences and progressed to malignancy. The overall malignancy rate was 4%. There was one mortality secondary to septic shock.Conclusions: Borderline ovarian tumors account for 10-20% of ovarian epithelial tumors and have extremely good prognosis affecting majorly the reproductive aged women. The low recurrence rate and good five year survival rate, at all the stages of the disease enables to incorporate fertility sparing surgeries as part of the staging.

Borderline Ovarian Tumors in Reproductive-Aged Women: Fertility-Sparing Surgery and Outcome

2004 ◽  
Vol 59 (3) ◽  
pp. 194-195
Author(s):  
John K. Chan ◽  
Yvonne G. Lin ◽  
Vera Loizzi ◽  
Mariam Ghobriel ◽  
Philip J. DiSaia ◽  
...  
Keyword(s):  
Ovarian Tumors ◽  
Borderline Ovarian Tumors ◽  
Fertility Sparing Surgery ◽  
Fertility Sparing ◽  
Reproductive Aged Women

scholarly journals Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Shuang Zhang ◽  
Shan Yu ◽  
Wenying Hou ◽  
Xiaoying Li ◽  
Chunping Ning ◽  
...  
Keyword(s):  
Ovarian Tumor ◽  
Menopausal Status ◽  
Area Under The Curve ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumor ◽  
Cancer Antigen 125 ◽  
Borderline Ovarian Tumors ◽  
Risk Of Malignancy ◽  
Risk Of Malignancy Index ◽  
Benign Ovarian Tumors

Abstract Background This study aimed to examine the performance of the four risk of malignancy index (RMI) in discriminating borderline ovarian tumors (BOTs) and benign ovarian masses in daily clinical practice. Methods A total of 162 women with BOTs and 379 women with benign ovarian tumors diagnosed at the Second Affiliated Hospital of Harbin Medical University from January 2012 to December 2016 were enrolled in this retrospective study. Also, we classified these patients into serous borderline ovarian tumor (SBOT) and mucinous borderline ovarian tumor (MBOT) subgroup. Preoperative ultrasound findings, cancer antigen 125 (CA125) and menopausal status were reviewed. The area under the curve (AUC) of receiver operator characteristic curves (ROC) and performance indices of RMI I, RMI II, RMI III and RMI IV were calculated and compared for discrimination between benign ovarian tumors and BOTs. Results RMI I had the highest AUC (0.825, 95% CI: 0.790–0.856) among the four RMIs in BOTs group. Similar results were found in SBOT (0.839, 95% CI: 0.804–0.871) and MBOT (0.791, 95% CI: 0.749–0.829) subgroups. RMI I had the highest specificity among the BOTs group (87.6, 95% CI: 83.9–90.7%), SBOT (87.6, 95% CI: 83.9–90.7%) and MBOT group (87.6, 95% CI: 83.9–90.7%). RMI II scored the highest overall in terms of sensitivity among the BOTs group (69.75, 95% CI: 62.1–76.7%), SBOT (74.34, 95% CI: 65.3–82.1%) and MBOT (59.18, 95% CI: 44.2–73.0%) group. Conclusion Compared to other RMIs, RMI I was the best-performed method for differentiation of BOTs from benign ovarian tumors. At the same time, RMI I also performed best in the discrimination SBOT from benign ovarian tumors.

Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors

2020 ◽  
Vol 157 (2) ◽  
pp. 411-417 ◽  
Author(s):  
Helmut Plett ◽  
Philipp Harter ◽  
Beyhan Ataseven ◽  
Florian Heitz ◽  
Sonia Prader ◽  
...  
Keyword(s):  
Ovarian Tumors ◽  
Reproductive Outcomes ◽  
Borderline Ovarian Tumors ◽  
Fertility Sparing Surgery ◽  
Fertility Sparing

Borderline Ovarian Tumors

2021 ◽  
pp. 223-239
Author(s):  
George Pados ◽  
Dimitrios Zouzoulas
Keyword(s):  
Ovarian Cancer ◽  
Gold Standard ◽  
Early Stage ◽  
Ovarian Tumors ◽  
Microscopic Appearance ◽  
Borderline Tumors ◽  
Non Invasive ◽  
Borderline Ovarian Tumors ◽  
Specific Subgroup ◽  
Serous Tumors

Borderline ovarian tumors (BOTs) are a specific subgroup of ovarian tumors and are characterized by cell proliferation and nuclear atypia without invasion or stromal invasion. They are usually more present in younger people than the invasive ovarian cancer and are diagnosed at an early stage and thus have a better prognosis. Histologically, borderline tumors are divided into serous (50%), mucosal (46%), and mixed (4%). The serous tumors are bilateral in 30% of the cases and are accompanied by infiltrations outside the ovary in 35% of the cases. These infiltrations may be non-invasive or invasive depending on their microscopic appearance and may affect treatment. Surgery is the approach of choice, and laparoscopic surgery, with the undeniable advantages it offers today, is the “gold standard.” All the surgical steps required to properly treat borderline tumors, at both diagnostic and therapeutic levels, can be safely and successfully be applied laparoscopically. Manipulations during surgery should be limited, and biopsies for rapid biopsy should be done within an endoscopic bag.

Sign in / Sign up

Export Citation Format

Share Document